You are here

P&T News

September 26

Medication is indicated for the treatment of seven inflammatory diseases
It is the first biologic that targets interleukin-12 and interleukin-23 cytokines active in the disease
The potential blockbuster was granted breakthrough therapy status in 2014
Drug previously approved for cryopyrin-associated periodic syndromes and active systemic juvenile idiopathic arthritis
Studies also will address HIV prevention among at-risk groups

September 23

Another facet of national opioid epidemic?
Treatment improves progression-free survival versus standard chemotherapy
Scientists demystify popular MS drug
Subcutaneous nanoparticles may help control autoimmune disorders

September 22

Sales staff downplayed drug’s addictive potential, court documents claim
Lantus gets the boot for diabetes
Participants could seek less-costly mix of patients, authors say
New study comes amid price-hike furor

September 21

Agency official overrules staff’s protests
Doctors dissatisfied with regulatory/paperwork burdens
Proposals are “unnecessary and ill-advised,” expert says
Once-daily canagliflozin/metformin combo lowers glucose
Anorectic drug is administered three times daily

Pages